Drug Monograph

Drug Name: **Dupixent® (dupilumab) 100 mg/0.67 mL syringe**
Drug Class: **Respiratory: Monoclonal Antibodies**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Dupixent is now available in a 100 mg/0.67 mL pre-filled syringe.
Manufacturer:	Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
Indications:	Dupixent is indicated for: • The treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. • As add-on maintenance treatment of patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. • As add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
Costs:	$1,601.70 per syringe. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.
Status Recommendation:	☐ Clinical Edit ☐ PA Required ☐ Open Access ☒ PDL
Type of PA Criteria:	☐ Appropriate Indications ☒ Non-Preferred ☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
Date: December 30, 2021